Molbio Diagnostics' IPO opened on August 10 and will close on August 12. A grey‑market premium of Rs 127 suggests a potential listing price about 15.7 % above the top of the price band, but investors must consider the associated risks.

Key Takeaways

  • IPO size: Rs 939.70 crore
  • Grey‑market premium: Rs 127
  • Day‑1 subscription: 0.83× overall

Molbio Diagnostics’ IPO opened on 10 August with a price band of Rs 768‑807 per share and a lot size of 18 shares. The issue, worth Rs 939.70 crore, will close on 12 August, with listing slated for 17 August on both BSE and NSE.

On the first day, the issue was subscribed only 0.83 times, indicating modest demand. Retail investors subscribed 0.77× while qualified institutional buyers hit a 1× subscription. The grey market, however, posted a premium of Rs 127, hinting at a possible listing price near Rs 934 – roughly a 15.7 % upside over the top of the price band.

Why This Matters

BozokMedia analysis shows that the premium reflects strong confidence in Molbio’s proprietary Truenat platform and its recurring‑revenue model, which could make the stock a lucrative medium‑ to long‑term play.

“Molbio’s growth trajectory and strategic acquisitions position it well for sustained earnings expansion.” – Equity Research Analyst
Did You Know?: Molbio’s test‑kit sales account for about 74 % of its FY26 revenue, underscoring the importance of its consumables business.

Frequently Asked Questions

  • Is the grey‑market premium a reliable indicator for the listing price? While it suggests market sentiment, the actual listing price can still deviate.
  • What are the main risks for investors? High customer concentration and dependence on TB testing are highlighted by brokerages.